Naked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia.

ABSTRACT: The treatment of childhood acute lymphoblastic leukemia (ALL) has reached overall survival rates exceeding 90%. The present and future challenges are to cure the remainder of patients still dying from disease, and to reduce morbidity and mortality in those who can be cured with standard-of-care chemotherapy by replacing toxic chemotherapy elements while retaining cure rates. With the novel therapeutic options introduced in the last years, including immunotherapies and targeted antibodies, the treatment of ALL is undergoing major changes. For B-cell precursor ALL, blinatumomab, an anti-CD19 bispecific antibody, has established its role in the consolidation treatment for both high- and standard-risk first relapse of ALL, in the presence of bone marrow involvement, and may also have an impact

SUBMITTER: Brivio E 

PROVIDER: S-EPMC11141655 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature